Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 4/14/2025 | $3.25 → $2.50 | Overweight | Piper Sandler |
| 5/28/2024 | $2.25 → $3.50 | Neutral → Overweight | Piper Sandler |
| 5/9/2024 | $8.00 | Neutral → Outperform | Wedbush |
| 5/6/2024 | $2.50 → $8.00 | Hold → Buy | Jefferies |
| 4/22/2024 | Underweight → Neutral | JP Morgan | |
| 11/14/2022 | $3.00 → $2.60 | Outperform → Market Perform | BMO Capital Markets |
| 7/7/2022 | $16.00 → $4.00 | Buy → Neutral | Mizuho |
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
H.C. Wainwright upgraded CytomX Therapeutics from Neutral to Buy and set a new price target of $5.00
Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously
Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, on
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma. CX-801 is a dually masked interferon (IFN) alpha-2b PROBODY® cytokine. CX-801 has been intentionally designed by CytomX to harness the power of Interferon alpha-2b's immune stimulating properties in combination with checkpoint inhibition. In
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions. The Company int